MannKind (NASDAQ:MNKD) Earns Sector Perform Rating from Royal Bank Of Canada

MannKind (NASDAQ:MNKD)‘s stock had its “sector perform” rating restated by research analysts at Royal Bank Of Canada in a note issued to investors on Friday, Marketbeat Ratings reports. They currently have a $3.50 price target on the biopharmaceutical company’s stock, down from their prior price target of $7.50. Royal Bank Of Canada’s target price would indicate a potential upside of 6.71% from the stock’s current price.

A number of other research firms have also recently weighed in on MNKD. Truist Financial set a $9.00 price objective on shares of MannKind in a research report on Monday, November 24th. Weiss Ratings reiterated a “hold (c)” rating on shares of MannKind in a report on Thursday, January 22nd. Zacks Research downgraded shares of MannKind from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 10th. Wall Street Zen raised shares of MannKind from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Finally, Wells Fargo & Company reduced their price objective on MannKind from $10.00 to $8.00 and set an “overweight” rating on the stock in a report on Tuesday, November 11th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $9.21.

MannKind Price Performance

Shares of MNKD stock opened at $3.28 on Friday. MannKind has a 1 year low of $2.93 and a 1 year high of $6.51. The stock’s 50 day simple moving average is $5.55 and its two-hundred day simple moving average is $5.36. The company has a market cap of $1.01 billion, a PE ratio of 164.08 and a beta of 0.84.

MannKind (NASDAQ:MNKD) last announced its earnings results on Thursday, February 26th. The biopharmaceutical company reported ($0.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.04). MannKind had a negative return on equity of 11.12% and a net margin of 1.68%.The company had revenue of $111.96 million during the quarter, compared to analysts’ expectations of $99.85 million. During the same quarter last year, the firm posted $0.03 EPS. MannKind’s revenue for the quarter was up 45.8% compared to the same quarter last year. Equities research analysts expect that MannKind will post 0.1 EPS for the current year.

Insider Buying and Selling

In other news, CEO Michael Castagna sold 65,804 shares of the firm’s stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $6.01, for a total transaction of $395,482.04. Following the completion of the transaction, the chief executive officer directly owned 2,504,792 shares in the company, valued at $15,053,799.92. This trade represents a 2.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Stuart A. Tross sold 47,006 shares of the firm’s stock in a transaction that occurred on Thursday, January 8th. The shares were sold at an average price of $6.33, for a total transaction of $297,547.98. Following the completion of the transaction, the insider directly owned 985,007 shares of the company’s stock, valued at $6,235,094.31. This represents a 4.55% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 262,846 shares of company stock worth $1,546,840 over the last three months. Insiders own 2.70% of the company’s stock.

Institutional Trading of MannKind

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Level Four Advisory Services LLC grew its holdings in shares of MannKind by 12.5% during the third quarter. Level Four Advisory Services LLC now owns 17,333 shares of the biopharmaceutical company’s stock worth $93,000 after buying an additional 1,925 shares during the last quarter. Franklin Resources Inc. lifted its holdings in shares of MannKind by 1.4% in the third quarter. Franklin Resources Inc. now owns 162,217 shares of the biopharmaceutical company’s stock valued at $871,000 after purchasing an additional 2,201 shares in the last quarter. Aaron Wealth Advisors LLC grew its holdings in MannKind by 1.2% during the 4th quarter. Aaron Wealth Advisors LLC now owns 200,763 shares of the biopharmaceutical company’s stock valued at $1,138,000 after buying an additional 2,355 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH raised its stake in MannKind by 7.8% in the 4th quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 33,405 shares of the biopharmaceutical company’s stock valued at $189,000 after purchasing an additional 2,404 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC boosted its position in MannKind by 6.6% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 39,234 shares of the biopharmaceutical company’s stock worth $220,000 after acquiring an additional 2,443 shares during the last quarter. Institutional investors and hedge funds own 49.55% of the company’s stock.

Trending Headlines about MannKind

Here are the key news stories impacting MannKind this week:

• Positive Sentiment: Revenue beat and growth outlook — MannKind reported Q4 revenue of about $112M (+46% YoY) and management outlined a roughly $450M 2026 revenue run‑rate while preparing an Afrezza pediatric launch, which supports longer‑term upside. MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
• Positive Sentiment: Analyst keeps “overweight” despite cut — Wells Fargo trimmed its price target from $8 to $7 but maintained an overweight rating, signaling continued analyst conviction in upside even after the EPS miss. Wells Fargo price target note
• Neutral Sentiment: Heavy options activity — Reports show large volume of call option purchases in MNKD, which can amplify intraday moves and reflects some speculative bullish positioning but is not a guarantee of sustained upside. Investors Purchase Large Volume of MannKind Call Options
• Neutral Sentiment: Mixed metric readouts — Analysts note revenue comfortably beat estimates while EPS missed (-$0.05 vs. -$0.01 expected), leaving valuation/forward EPS expectations in flux—important context but mixed for immediate direction. MannKind Reports Q4 Loss, Tops Revenue Estimates
• Negative Sentiment: EPS miss and unexpected quarterly loss drove the sell‑off — The bottom‑line shortfall led to a sharp intraday drop and a 52‑week low as investors reacted negatively to the EPS miss despite revenue growth. Why MannKind Stock Tumbled on Thursday
• Negative Sentiment: RBC cut price target sharply — Royal Bank of Canada cut its target from $7.50 to $3.50 (sector perform), reducing near‑term analyst support and adding selling pressure. RBC rating/price target note
• Negative Sentiment: Broader biotech weakness — A sector‑wide pullback (“biotech bloodbath”) this week has dragged MNKD along with peers, amplifying downside from company‑specific negatives. Biotech Bloodbath Drags Health Care Down as MannKind and Soleno Stocks Sink
• Negative Sentiment: Competitive risk flagged — News that United Therapeutics is considering a new treprostinil formulation pressured MannKind (and peers), introducing potential product/market risk for inhaled/treprostinil formulations. United Therapeutics mulls new treprostinil formulation

MannKind Company Profile

MannKind Corporation is a biopharmaceutical company specialized in the development and commercialization of inhaled therapeutic products. The company’s core business revolves around its proprietary Technosphere® drug‐delivery platform, which is designed to enable rapid absorption of small‐molecule drugs through pulmonary administration. MannKind’s lead product, Afrezza®, is an inhaled insulin therapy intended for adults with type 1 and type 2 diabetes, offering users a rapid‐acting alternative to traditional injectable insulins.

Afrezza received U.S.